What is Duchenne muscular dystrophy (DMD)?

Duchenne muscular dystrophy is a rare genetic disorder primarily affecting boys, causing progressive muscle fibre breakdown due to a lack of the protein dystrophin. Symptoms typically begin around age three.

What is givinostat and how does it help DMD patients?

Givinostat is a new drug approved for NHS rollout that may help eligible patients with Duchenne muscular dystrophy maintain their mobility for longer, potentially extending the time before they lose the ability to walk by about five years.

Why is the approval of givinostat significant for DMD families?

The approval of givinostat is significant because it offers a new treatment option for Duchenne muscular dystrophy, providing hope for prolonged mobility and better quality of life, despite a lengthy and challenging approval process.

New Hope for Duchenne Boys: NHS Approves Lifesaving Drug

8 May

Summary

Givinostat drug approved by NHS for Duchenne muscular dystrophy treatment.
Drug may help eligible patients maintain mobility for an additional five years.
Approval follows a two-year process, with concerns over delayed access.

New Hope for Duchenne Boys: NHS Approves Lifesaving Drug

Givinostat, a new treatment for Duchenne muscular dystrophy (DMD), has received approval for rollout on the NHS in England, offering a significant breakthrough for affected children.

The National Institute for Health and Care Excellence (Nice) confirmed the drug's availability after its manufacturer reached a commercial agreement with NHS England. Givinostat, also known as Duvyzat, is indicated for DMD patients aged six and older who can still walk or stand.

Clinical trials suggest that givinostat can extend the period before patients lose the ability to walk by approximately five years. Nice estimates that around 530 individuals in England will benefit from this treatment.

The drug had been available through an early access program since 2024, but families reported difficulties in accessing it based on their location, leading to concerns about a postcode lottery. Campaigners have highlighted the "agonising" two-year wait for this approval, during which many children's conditions worsened.

Duchenne UK welcomed the decision, calling it a "significant breakthrough." However, they also expressed disappointment that the approval is currently restricted to patients who can still walk or stand, urging stakeholders to find ways to make the treatment available to all eligible patients, including those who have lost mobility.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Home / Health / New Hope for Duchenne Boys: NHS Approves Lifesaving Drug

New Hope for Duchenne Boys: NHS Approves Lifesaving Drug

8 May

•

Summary

Givinostat drug approved by NHS for Duchenne muscular dystrophy treatment.
Drug may help eligible patients maintain mobility for an additional five years.
Approval follows a two-year process, with concerns over delayed access.

Givinostat, a new treatment for Duchenne muscular dystrophy (DMD), has received approval for rollout on the NHS in England, offering a significant breakthrough for affected children.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.